Department of Biology, University of Texas at Arlington, Arlington, Texas 76019, USA.
Nat Rev Microbiol. 2011 Jan;9(1):62-75. doi: 10.1038/nrmicro2474.
Persistent infections involving slow-growing or non-growing bacteria are hard to treat with antibiotics that target biosynthetic processes in growing cells. Consequently, there is a need for antimicrobials that can treat infections containing dormant bacteria. In this Review, we discuss the emerging concept that disrupting the bacterial membrane bilayer or proteins that are integral to membrane function (including membrane potential and energy metabolism) in dormant bacteria is a strategy for treating persistent infections. The clinical applicability of these approaches is exemplified by the efficacy of lipoglycopeptides that damage bacterial membranes and of the diarylquinoline TMC207, which inhibits membrane-bound ATP synthase. Despite some drawbacks, membrane-active agents form an important new means of eradicating recalcitrant, non-growing bacteria.
持续性感染涉及生长缓慢或不生长的细菌,用针对生长细胞生物合成过程的抗生素很难治疗。因此,需要有能够治疗含有休眠细菌的感染的抗菌药物。在这篇综述中,我们讨论了一个新出现的概念,即破坏休眠细菌的细菌膜双层或对膜功能(包括膜电位和能量代谢)至关重要的蛋白质是治疗持续性感染的一种策略。糖肽类抗生素破坏细菌膜的疗效和二芳基喹啉 TMC207 抑制膜结合 ATP 合酶的疗效证明了这些方法的临床适用性。尽管存在一些缺点,但膜活性药物形成了根除顽固、不生长细菌的一种重要新手段。